Mumbai:Divi’s Labs web benefit rises over 67 consistent with cent, pronounces dividend of Rs 30 consistent with percentage Highlights Pharma primary Divi’s Laboratories Ltd on Saturday reported a 67.6 consistent with cent upward thrust in its consolidated web benefit at Rs 538 crore for the January-March quarter of 2024, as in opposition to Rs 321 crore in the similar duration final 12 months.
Pharma primary Divi’s Laboratories Ltd on Saturday reported a 67.6 consistent with cent upward thrust in its consolidated web benefit to Rs 538 crore for the January-March quarter of 2024, as in opposition to Rs 321 crore in the similar duration final 12 months. Earnings for the quarter grew 18 consistent with cent to Rs 2,303 crore as in opposition to Rs 1,951 crore in the similar duration a 12 months in the past. The corporate’s board has beneficial a last dividend of Rs 30 consistent with fairness percentage of face worth of Rs 2 every for the monetary 12 months ended March 31, 2024, matter to the approval of the contributors on the company’s annual normal assembly.
Profits earlier than hobby, tax, depreciation and amortization rose to Rs 731 crore from Rs 473 crore in the similar duration a 12 months in the past. Divi’s Laboratories is a pharmaceutical and biotechnology corporate engaged within the industry of generic APIs, customized synthesis and nutraceuticals. The corporate is called after its promoter Dr. Murali Ok. Divi. It markets healing medicine for spaces equivalent to cardiovascular, anti inflammatory, anti-cancer and central worried gadget illnesses.
